ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Antibody-Drug Conjugates - Lessons Learned
May 20, 2022Antibody-drug conjugates (ADCs) have made significant progress in tumor therapy and show a promising future. -
Breaking News! The Second ADC Approved for Marketing in China
May 21, 2020According to the NMPA website on May 13, the marketing application for Brentuximab Vedotin Injection filed by Takeda Pharmaceutical in China has been reviewed and approved, to become the second ADC approved for marketing in China. -
NICE backing for Keytruda in classical Hodgkin lymphoma
July 27, 2018The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma. -
US expands scope of Seattle Genetics’ Adcetris
July 23, 2018US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Pharma Sources Insight January 2025
